UY35154A - ANTICUERPOS MONOCLONALES CONTRA UNA PROTEÍNA ACTIVADA C (aPC) - Google Patents
ANTICUERPOS MONOCLONALES CONTRA UNA PROTEÍNA ACTIVADA C (aPC)Info
- Publication number
- UY35154A UY35154A UY0001035154A UY35154A UY35154A UY 35154 A UY35154 A UY 35154A UY 0001035154 A UY0001035154 A UY 0001035154A UY 35154 A UY35154 A UY 35154A UY 35154 A UY35154 A UY 35154A
- Authority
- UY
- Uruguay
- Prior art keywords
- apc
- activated protein
- monoclonal antibodies
- antibodies against
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente memoria se proporcionan anticuerpos, fragmentos de anticuerpos de unión a antígenos (Fabs) y otras proteínas de andamiaje, dirigidos contra proteína C activada humana (aPC) con unión mínima a su zimógeno de Proteína C (PC). Asimismo, estas proteínas de unión a aPC podrían bloquear potencialmente la actividad anticoagulante de aPC para inducir la coagulación. En la presente memoria se describen los usos terapéuticos de estos unidores así como también los métodos de selección y cribado de anticuerpos específicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731294P | 2012-11-29 | 2012-11-29 | |
US201361786472P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35154A true UY35154A (es) | 2014-06-30 |
Family
ID=50828462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035154A UY35154A (es) | 2012-11-29 | 2013-11-28 | ANTICUERPOS MONOCLONALES CONTRA UNA PROTEÍNA ACTIVADA C (aPC) |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150307625A1 (es) |
EP (1) | EP2925351A4 (es) |
JP (1) | JP2016501230A (es) |
KR (1) | KR20150088869A (es) |
CN (1) | CN104812402A (es) |
AR (1) | AR093671A1 (es) |
AU (1) | AU2013352159A1 (es) |
BR (1) | BR112015012414A2 (es) |
CA (1) | CA2892750A1 (es) |
HK (1) | HK1212896A1 (es) |
IL (1) | IL238658A0 (es) |
MX (1) | MX2015006424A (es) |
RU (1) | RU2015125349A (es) |
SG (1) | SG11201503719WA (es) |
TW (1) | TW201429992A (es) |
UY (1) | UY35154A (es) |
WO (1) | WO2014085596A1 (es) |
ZA (1) | ZA201504659B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017087391A1 (en) * | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
EP3831843A1 (en) * | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
CN115611986A (zh) * | 2021-07-13 | 2023-01-17 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
CN116496394A (zh) * | 2022-01-26 | 2023-07-28 | 东莞市朋志生物科技有限公司 | 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒 |
WO2023168429A2 (en) * | 2022-03-04 | 2023-09-07 | Coagulant Therapeutics Corporation | Camelid antibodies against activated protein c and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
WO1997040145A1 (en) * | 1996-04-24 | 1997-10-30 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
AU2001296483B2 (en) * | 2000-10-02 | 2006-02-16 | Oklahoma Medical Research Foundation | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20030203355A1 (en) * | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
WO2006017538A2 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
AU2005318171B2 (en) * | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
EP1979001B1 (en) * | 2005-12-13 | 2012-04-11 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
MX2010004615A (es) * | 2007-10-26 | 2010-07-06 | Oklahoma Med Res Found | Anticuerpos monoclonales contra proteina c. activada e inactivada. |
GB0903151D0 (en) * | 2009-02-25 | 2009-04-08 | Bioinvent Int Ab | Antibody uses and methods |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
GB201011771D0 (en) * | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
EP2640421A4 (en) * | 2010-11-16 | 2014-05-28 | Medimmune Llc | THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES |
US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2013
- 2013-11-27 JP JP2015545438A patent/JP2016501230A/ja active Pending
- 2013-11-27 WO PCT/US2013/072243 patent/WO2014085596A1/en active Application Filing
- 2013-11-27 RU RU2015125349A patent/RU2015125349A/ru not_active Application Discontinuation
- 2013-11-27 US US14/443,710 patent/US20150307625A1/en not_active Abandoned
- 2013-11-27 CN CN201380062159.XA patent/CN104812402A/zh active Pending
- 2013-11-27 CA CA2892750A patent/CA2892750A1/en not_active Abandoned
- 2013-11-27 EP EP13857869.5A patent/EP2925351A4/en not_active Withdrawn
- 2013-11-27 AU AU2013352159A patent/AU2013352159A1/en not_active Abandoned
- 2013-11-27 MX MX2015006424A patent/MX2015006424A/es unknown
- 2013-11-27 BR BR112015012414A patent/BR112015012414A2/pt not_active IP Right Cessation
- 2013-11-27 KR KR1020157017008A patent/KR20150088869A/ko not_active Application Discontinuation
- 2013-11-27 SG SG11201503719WA patent/SG11201503719WA/en unknown
- 2013-11-28 UY UY0001035154A patent/UY35154A/es not_active Application Discontinuation
- 2013-11-28 TW TW102143366A patent/TW201429992A/zh unknown
- 2013-11-29 AR ARP130104417A patent/AR093671A1/es unknown
-
2015
- 2015-05-06 IL IL238658A patent/IL238658A0/en unknown
- 2015-06-26 ZA ZA2015/04659A patent/ZA201504659B/en unknown
-
2016
- 2016-01-27 HK HK16100878.9A patent/HK1212896A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL238658A0 (en) | 2015-06-30 |
BR112015012414A2 (pt) | 2017-09-12 |
HK1212896A1 (zh) | 2016-06-24 |
ZA201504659B (en) | 2017-11-29 |
MX2015006424A (es) | 2015-08-14 |
TW201429992A (zh) | 2014-08-01 |
JP2016501230A (ja) | 2016-01-18 |
WO2014085596A1 (en) | 2014-06-05 |
AR093671A1 (es) | 2015-06-17 |
EP2925351A1 (en) | 2015-10-07 |
RU2015125349A (ru) | 2017-01-10 |
SG11201503719WA (en) | 2015-06-29 |
KR20150088869A (ko) | 2015-08-03 |
CN104812402A (zh) | 2015-07-29 |
AU2013352159A1 (en) | 2015-06-04 |
CA2892750A1 (en) | 2014-06-05 |
US20150307625A1 (en) | 2015-10-29 |
EP2925351A4 (en) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20150360A1 (es) | Agentes de union de proteina de r-espondina humana (rsp03) y usos de los mismos | |
EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201591020A1 (ru) | Человеческие анти-тау антитела | |
EA201890013A1 (ru) | Способы получения tcr гамма дельтат-клеток | |
EP4249065A3 (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors | |
CR20130132A (es) | Anticuerpos contra metalproteasa-9 de matriz | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
CR20120105A (es) | Proteínas terapéuticas de unión a dll4 | |
UY33319A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
EA201492101A1 (ru) | Антитела против fcrn | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
ECSP14001260A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
DOP2013000178A (es) | Tratamiento de la osteoartritis y del dolor | |
EA201391312A1 (ru) | Антитело к человеческому тканевому фактору и его применение | |
ECSP11011445A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b | |
UY35154A (es) | ANTICUERPOS MONOCLONALES CONTRA UNA PROTEÍNA ACTIVADA C (aPC) | |
EA201690503A1 (ru) | Антитела | |
EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210707 |